Under his leadership, CCS Medical’s annual sales grew from about $60 million to over $500 million. Additionally, he was responsible for acquiring and integrating Becton Dickenson’s blood glucose monitoring division into the CCS product line and commercializing it under the Nova Max brand. Capper also served as an officer in the US Navy earlier in his career. He holds a Bachelor of Science in Accounting from West Chester University and an MBA in International Finance from George Washington University.

“On behalf of the board I would like to thank Dick for his commitment and assistance during this transition period,” said George H. Holley, Chairman of the Board of Home Diagnostics. “We extend our best wishes to him and appreciate the leadership he provided to Home Diagnostics during the last eight years which includes the company’s successful public offering.”

“I am pleased to appoint Joe Capper to the positions of CEO and President of Home Diagnostics and welcome him to the Board of Directors,” said Holley. “Joe garnered extensive experience in the diabetes industry during his tenure at Bayer and CCS Medical and has an understanding of our distribution channels as well as operations and supply chain management. Joe is the ideal leader to join our existing strong management team in order to move Home Diagnostics to the next stage of growth by maximizing our current product expansion and capitalizing on the strength of our distribution network.”

“I have been familiar with Home Diagnostics as a business partner for many years and look forward to leveraging my experience in the field to help accelerate the growth and expansion of our business,” said Joe Capper, President and CEO of Home Diagnostics. “I have great respect for the company’s ability to innovate, the product portfolio and the market position they have achieved in the industry. I am extremely excited about the opportunity to join the Home Diagnostics team and look forward to capitalizing on our strong product line and market position.”